logo
logo

Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology

Jan 19, 2021•over 4 years ago

Amount Raised

$1 Million

Round Type

seed

WashingtonNon ProfitHealth Care

Description

 Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $1 million programmatic investment in Satellos Bioscience Inc. (Satellos) to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.

Company Information

Company

Parent Project Muscular Dystrophy

Location

Washington, District Of Columbia, United States

About

Parent Project Muscular Dystrophy (PPMD) is a nonprofit organization dedicated to ending Duchenne, a genetic disorder that gradually weakens muscles. Since its founding in 1994, PPMD has fought to ensure families have access to expert care, cutting-edge treatments, and a strong support community. The organization invests deeply in therapies for today’s patients while driving research for future generations, and its advocacy efforts have secured hundreds of millions in funding and led to eight FDA approvals. Everything PPMD does is aimed at helping those with Duchenne live longer, stronger lives—and it will not rest until the disease is ended for all.

Related People